mometazon furoat for atopic dermatitis in children
Clicks: 263
ID: 159776
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
263 views
38 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #1 of 6 articles by views in life sciences in space research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Atopic dermatitis is one of the most prevalent reasons for skin lesions in the infancy. The medications of the first line therapy for this disease are topic glucocorticosteroids (TGCS). The survey has analyzed the efficiency of a new TGCS — mometazon furoat — for treating atopic dermatitis of children. The action mechanism of this medication is connected with the suppression of proinflammatory cytokinins synthesis (Il6, Il1, TNF). Mometazon furoat has clear anti inflammatory, antipruritic and anti exudative action. The treatment results proved high efficiency of the medication both for noncomplicated atopic dermatitis and for atopic dermatitis complicated with a secondary infection.Key words: atopic dermatitis, topic glucocorticosteroids, therapy, children.
| Reference Key |
shaipov2007pediatrieskamometazon
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;T.S. Shaipov;L.P. Mazitova |
| Journal | life sciences in space research |
| Year | 2007 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.